Last reviewed · How we verify
ALX1-11 (drug)
ALX1-11 is a monoclonal antibody that blocks the Wnt signaling pathway by targeting Wnt ligands, thereby inhibiting aberrant cell proliferation and differentiation.
ALX1-11 is a monoclonal antibody that blocks the Wnt signaling pathway by targeting Wnt ligands, thereby inhibiting aberrant cell proliferation and differentiation. Used for Wnt-driven cancers (investigational).
At a glance
| Generic name | ALX1-11 (drug) |
|---|---|
| Also known as | PREOS |
| Sponsor | Shire |
| Drug class | Wnt signaling inhibitor (monoclonal antibody) |
| Target | Wnt ligands |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ALX1-11 binds to and neutralizes Wnt ligands, which are secreted signaling molecules involved in developmental and regenerative processes. By blocking Wnt signaling, the drug aims to reduce pathological cell growth and proliferation in conditions where this pathway is dysregulated. This mechanism is particularly relevant in oncology and certain genetic disorders characterized by excessive Wnt pathway activation.
Approved indications
- Wnt-driven cancers (investigational)
Common side effects
- Infusion-related reactions
- Fatigue
- Nausea
Key clinical trials
- Calcium Supplementation in Postmenopausal Women (PHASE3)
- Open Label Extension Study of PREOS (PHASE3)
- Open Label Extension (PHASE3)
- A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis (PHASE2)
- TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALX1-11 (drug) CI brief — competitive landscape report
- ALX1-11 (drug) updates RSS · CI watch RSS
- Shire portfolio CI